pubmed-article:10638559 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:10638559 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
pubmed-article:10638559 | lifeskim:mentions | umls-concept:C0034665 | lld:lifeskim |
pubmed-article:10638559 | lifeskim:mentions | umls-concept:C1704410 | lld:lifeskim |
pubmed-article:10638559 | lifeskim:mentions | umls-concept:C0549178 | lld:lifeskim |
pubmed-article:10638559 | lifeskim:mentions | umls-concept:C0442113 | lld:lifeskim |
pubmed-article:10638559 | lifeskim:mentions | umls-concept:C1442466 | lld:lifeskim |
pubmed-article:10638559 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:10638559 | pubmed:dateCreated | 2000-2-4 | lld:pubmed |
pubmed-article:10638559 | pubmed:abstractText | To investigate further the phenomenon of pharmacological tolerance to H2-receptor antagonists, we undertook a study of the antisecretory effect of ranitidine with continuous daily administration. | lld:pubmed |
pubmed-article:10638559 | pubmed:language | eng | lld:pubmed |
pubmed-article:10638559 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10638559 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:10638559 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10638559 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10638559 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:10638559 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:10638559 | pubmed:month | Jan | lld:pubmed |
pubmed-article:10638559 | pubmed:issn | 0002-9270 | lld:pubmed |
pubmed-article:10638559 | pubmed:author | pubmed-author:LachmanLL | lld:pubmed |
pubmed-article:10638559 | pubmed:author | pubmed-author:HowdenC WCW | lld:pubmed |
pubmed-article:10638559 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:10638559 | pubmed:volume | 95 | lld:pubmed |
pubmed-article:10638559 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:10638559 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:10638559 | pubmed:pagination | 57-61 | lld:pubmed |
pubmed-article:10638559 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:meshHeading | pubmed-meshheading:10638559... | lld:pubmed |
pubmed-article:10638559 | pubmed:year | 2000 | lld:pubmed |
pubmed-article:10638559 | pubmed:articleTitle | Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. | lld:pubmed |
pubmed-article:10638559 | pubmed:affiliation | Phoenix International (formerly IBRD Center for Clinical Research), Neptune, New Jersey, USA. | lld:pubmed |
pubmed-article:10638559 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:10638559 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10638559 | lld:pubmed |